Shionogi’s oral antiviral for respiratory syncytial virus (RSV) has met its primary endpoint in a Phase II study.

S-337395 is an investigational oral antiviral candidate for RSV infection that inhibits the activity of the L protein, which is essential for virus replication. 1,2 Furthermore, this drug has received ...

Clinical symptoms of the virus are usually mild and like those caused by human respiratory syncytial virus (RSV ... response activates interferons and cytokines to control viral replication, while the ...

The innate response activates interferons and cytokines to control viral replication ... HMPV is far closer to influenza and respiratory syncytial virus (RSV) than pneumonia.

A 3D reconstruction of a mouse lung four days after infection with fluorescent Sendai virus reveals widespread virus presence (red) and active replication (green). A study by researchers at WashU ...

HMPV belongs to the Paramyxoviridae family, a group of viruses that also includes the respiratory syncytial virus (RSV), according ... in terms of structure, replication mechanisms, and how ...

It is also possible for people to get infected from contact with a sick cat, Troisi said. The situation with the virus is ...

Respiratory syncytial virus (RSV) is a leading cause of lower respiratory tract infections in children under two years old, resulting in significant morbidity and a heavy economic burden on healthcare ...

It’s what’s being called a “Quad-demic,” with cases on the rise for COVID-19, Respiratory syncytial virus (RSV), Influenza, ...

A virus rapidly spreading in China is also circulating in the United States, causing concern among health experts.